Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
BÀI TỔNG QUAN Issue: Số 107S BỆNH SUY TIM

Updates on heart failure management in 2023

Phan Tuấn Đạt: Viện Tim mạch Việt Nam, Bệnh viện Bạch Mai; Hoàng Phi Điệp: Bệnh viện Đông Đô; Nguyễn Ngọc Quang: Đại học Y Hà Nội; Phạm Mạnh Hùng: Trường Đại học Y Hà Nội; Đỗ Doãn Lợi: Trường Đại học Y Hà Nội;
Published: January 20, 2024
Views: 12

Abstract

Heart failure, a prevalent global health issue affecting over 64 million people worldwide1 and the leading single cause of hospitalization in the USA and Europe. Previously regarded as a dismal condition, the heart failure prognosis was often compare to many cancers. In the past few years, heart failure has undergone a revolution with some new medications and device-based therapies. In 2023, although the number of “blockbuster” studies has begun to decline, many other advances in cardiology had links to heart failure.

Keywords
heart failure 2023

References

1.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
2.
Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020;22(Suppl L):L77-L81. doi:10.1093/eurheartj/suaa140
3.
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
4.
Packer M, Butler J, Zannad F, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021;144(16):1284-1294. doi:10.1161/CIRCULATIONAHA.121.056824
5.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963
6.
James S, Erlinge D, Storey RF, et al. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Am Heart J. 2023;266:188-197. doi:10.1016/j.ahj.2023.08.008
7.
Cheang I, Yao W, Zhou Y, et al. Efficacy and Safety of Qiliqiangxin in Patients with Heart Failure and Reduced Ejection Fraction: The QUEST Randomised Clinical Trial.
8.
Mentz RJ, Garg J, Rockhold FW, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023;389(11):975-986. doi:10.1056/NEJMoa2304968
Updates on heart failure management in 2023

Files

Article Views12
Document Views0
Downloads0
Section BÀI TỔNG QUAN
Issue Số 107S
Category BỆNH SUY TIM
Pages 32-42
Copyright Holder 2024 Tạp chí Tim mạch học Việt Nam